drugset / Trial / NCT07575906

A Study to Learn How a Single Dose of the Study Medicine Called PF-08057418 is Tolerated in the Body of Healthy Adults.

NCT07575906 ↗

Phase 1 Recruiting 8 enrolled Pfizer
RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this clinical trial is to learn about the safety and pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from body after participant take it) of the study medicine (called PF-08057418) in healthy people. This study is seeking participants who are healthy adults. Everyone who participates in this study will receive the study medicine. The study medicine may be given as a solution or as a tablet. Participants will be dosed once a week for 5 weeks. The investigator will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe. Participants will be involved in this study for up to 13 weeks from screening to follow-up visit. Participants stay in the study clinic for the 5 week dosing duration of the study, with two follow-up visits subsequently, either in person or by telephone call.

Timeline

Start
2026-05-08
Primary completion
2026-07-23
Completion
2026-07-23

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-08057418 Unknown — Oral

Indications

No indication recorded.